Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Lexeo Therapeutics, Inc. (LXEO)

BridgeBio Oncology Therapeutics, Inc and Lexeo Therapeutics, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Lexeo Therapeutics, Inc. are of similar size ($236.5M and $226.6M). Across the 10 metrics below, Lexeo Therapeutics, Inc. leads on 6 and BridgeBio Oncology Therapeutics, Inc on 4.

Valuation

Metric BBOT LXEO Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.70 0.96 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (97.87%) (43.56%) (33.15%)
Free cash flow yield (67.14%) (39.24%) (25.50%)

Profitability

Metric BBOT LXEO Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (252.10%) (46.76%) (56.36%)
Return on assets (96.69%) (40.50%) (48.04%)
Return on invested capital (127.66%) (253.48%) 0.00%

Growth

Metric BBOT LXEO Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 99.93% 39.81% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 13.89 4.72
Net debt to EBITDA 2.93 1.67 0.96

Dividend

Metric BBOT LXEO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT LXEO Biotechnology median
Market cap 236.52m 226.56m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack